The Philippines’ HPV vaccination program began as a community-based pilot in 2013 and expanded to school-based delivery by 2015, targeting grade 4 pupils aged 9–14. Coverage initially reached 80%+ but dropped sharply after 2017 due to vaccine controversies and further during COVID-19 when services shifted back to community delivery. Key challenges include high vaccine cost […]
Topic: Programme scale-up
Country presentation: challenges for scale-up to the National level – China
China has not yet integrated HPV vaccination into its national immunization program, though several provinces and cities have launched locally funded or philanthropic initiatives targeting girls aged 12–15. Coverage remains low at 4% by 2022, despite over 85 million doses administered since 2017. The facility‑based strategy relies on strong collaboration between health, education, and finance […]
China: Roadmap to national introduction
China’s HPV vaccination landscape has significantly advanced with the recent approval of the first domestically produced nine-valent vaccine, Cecolin-9, in 2025. Alongside this, expanded indications now allow HPV vaccination for males aged 9–26. The country currently has multiple licensed vaccines, including domestic bivalent and imported quadrivalent and nine-valent options, ensuring broad supply capacity. By May […]
Panel Discussion and Input from participants: Strategies and Lessons for Scaling Up to national HPV Vaccination.
The panel focused on transitioning HPV vaccination programs from subnational pilots to national scale, featuring insights from China, Vietnam, Indonesia, and the Philippines. Speakers emphasized key barriers, including financing, policy constraints, supply challenges, and decentralized health systems affecting coordination and equity. China highlighted legal reforms and public education needs; Vietnam stressed advocacy and multi-ministerial support; […]